Financhill
Buy
68

BSX Quote, Financials, Valuation and Earnings

Last price:
$99.18
Seasonality move :
6.11%
Day range:
$96.52 - $99.41
52-week range:
$66.16 - $107.17
Dividend yield:
0%
P/E ratio:
79.12x
P/S ratio:
8.78x
P/B ratio:
6.70x
Volume:
5.7M
Avg. volume:
7.9M
1-year change:
49.33%
Market cap:
$146B
Revenue:
$16.7B
EPS (TTM):
$1.25

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BSX
Boston Scientific
$4.4B $0.66 18.49% 103.33% $115.62
ABT
Abbott Laboratories
$11B $1.34 4.19% 52.11% $136.81
ISRG
Intuitive Surgical
$2.2B $1.79 15.66% 15.62% $630.35
PODD
Insulet
$582M $1.02 23.07% 6.17% $314.06
RMD
ResMed
$1.3B $2.31 7.21% 15.65% $269.38
SYK
Stryker
$6.4B $3.87 8.28% 33.5% $424.43
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BSX
Boston Scientific
$98.90 $115.62 $146B 79.12x $0.00 0% 8.78x
ABT
Abbott Laboratories
$127.64 $136.81 $221.4B 16.69x $0.59 1.76% 5.32x
ISRG
Intuitive Surgical
$488.80 $630.35 $174.3B 76.26x $0.00 0% 21.19x
PODD
Insulet
$261.63 $314.06 $18.4B 45.19x $0.00 0% 9.33x
RMD
ResMed
$224.74 $269.38 $33B 26.53x $0.53 0.92% 6.73x
SYK
Stryker
$373.49 $424.43 $142.5B 48.13x $0.84 0.87% 6.37x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BSX
Boston Scientific
32.79% 0.683 8.05% 0.46x
ABT
Abbott Laboratories
22.86% 0.603 7.72% 1.23x
ISRG
Intuitive Surgical
-- 1.599 -- 3.08x
PODD
Insulet
53.47% 1.510 7.6% 2.50x
RMD
ResMed
11.35% 0.169 2% 1.74x
SYK
Stryker
39.72% 1.452 10.13% 1.11x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BSX
Boston Scientific
$3.1B $790M 5.97% 8.96% 14.58% $1.2B
ABT
Abbott Laboratories
$6B $1.9B 24.06% 32.63% 19.74% $2.1B
ISRG
Intuitive Surgical
$1.6B $734.9M 15.6% 15.6% 30.45% $510.6M
PODD
Insulet
$430.9M $109.3M 17.64% 43.11% 20.08% $91.7M
RMD
ResMed
$751.3M $417.2M 21.74% 25.56% 32.54% $285.2M
SYK
Stryker
$4.2B $1.6B 9.04% 15.22% 24.21% $1.7B

Boston Scientific vs. Competitors

  • Which has Higher Returns BSX or ABT?

    Abbott Laboratories has a net margin of 12.41% compared to Boston Scientific's net margin of 84.1%. Boston Scientific's return on equity of 8.96% beat Abbott Laboratories's return on equity of 32.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    BSX
    Boston Scientific
    67.86% $0.38 $32.6B
    ABT
    Abbott Laboratories
    54.97% $5.27 $62B
  • What do Analysts Say About BSX or ABT?

    Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 16.91%. On the other hand Abbott Laboratories has an analysts' consensus of $136.81 which suggests that it could grow by 7.18%. Given that Boston Scientific has higher upside potential than Abbott Laboratories, analysts believe Boston Scientific is more attractive than Abbott Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    BSX
    Boston Scientific
    23 4 0
    ABT
    Abbott Laboratories
    13 7 0
  • Is BSX or ABT More Risky?

    Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.418%.

  • Which is a Better Dividend Stock BSX or ABT?

    Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.76% to investors and pays a quarterly dividend of $0.59 per share. Boston Scientific pays -- of its earnings as a dividend. Abbott Laboratories pays out 28.62% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BSX or ABT?

    Boston Scientific quarterly revenues are $4.6B, which are smaller than Abbott Laboratories quarterly revenues of $11B. Boston Scientific's net income of $566M is lower than Abbott Laboratories's net income of $9.2B. Notably, Boston Scientific's price-to-earnings ratio is 79.12x while Abbott Laboratories's PE ratio is 16.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.78x versus 5.32x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BSX
    Boston Scientific
    8.78x 79.12x $4.6B $566M
    ABT
    Abbott Laboratories
    5.32x 16.69x $11B $9.2B
  • Which has Higher Returns BSX or ISRG?

    Intuitive Surgical has a net margin of 12.41% compared to Boston Scientific's net margin of 28.41%. Boston Scientific's return on equity of 8.96% beat Intuitive Surgical's return on equity of 15.6%.

    Company Gross Margin Earnings Per Share Invested Capital
    BSX
    Boston Scientific
    67.86% $0.38 $32.6B
    ISRG
    Intuitive Surgical
    68.04% $1.88 $16.5B
  • What do Analysts Say About BSX or ISRG?

    Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 16.91%. On the other hand Intuitive Surgical has an analysts' consensus of $630.35 which suggests that it could grow by 28.96%. Given that Intuitive Surgical has higher upside potential than Boston Scientific, analysts believe Intuitive Surgical is more attractive than Boston Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    BSX
    Boston Scientific
    23 4 0
    ISRG
    Intuitive Surgical
    14 10 0
  • Is BSX or ISRG More Risky?

    Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.616%.

  • Which is a Better Dividend Stock BSX or ISRG?

    Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BSX or ISRG?

    Boston Scientific quarterly revenues are $4.6B, which are larger than Intuitive Surgical quarterly revenues of $2.4B. Boston Scientific's net income of $566M is lower than Intuitive Surgical's net income of $685.7M. Notably, Boston Scientific's price-to-earnings ratio is 79.12x while Intuitive Surgical's PE ratio is 76.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.78x versus 21.19x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BSX
    Boston Scientific
    8.78x 79.12x $4.6B $566M
    ISRG
    Intuitive Surgical
    21.19x 76.26x $2.4B $685.7M
  • Which has Higher Returns BSX or PODD?

    Insulet has a net margin of 12.41% compared to Boston Scientific's net margin of 16.85%. Boston Scientific's return on equity of 8.96% beat Insulet's return on equity of 43.11%.

    Company Gross Margin Earnings Per Share Invested Capital
    BSX
    Boston Scientific
    67.86% $0.38 $32.6B
    PODD
    Insulet
    72.12% $1.39 $2.6B
  • What do Analysts Say About BSX or PODD?

    Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 16.91%. On the other hand Insulet has an analysts' consensus of $314.06 which suggests that it could grow by 20.04%. Given that Insulet has higher upside potential than Boston Scientific, analysts believe Insulet is more attractive than Boston Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    BSX
    Boston Scientific
    23 4 0
    PODD
    Insulet
    14 4 0
  • Is BSX or PODD More Risky?

    Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison Insulet has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.544%.

  • Which is a Better Dividend Stock BSX or PODD?

    Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BSX or PODD?

    Boston Scientific quarterly revenues are $4.6B, which are larger than Insulet quarterly revenues of $597.5M. Boston Scientific's net income of $566M is higher than Insulet's net income of $100.7M. Notably, Boston Scientific's price-to-earnings ratio is 79.12x while Insulet's PE ratio is 45.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.78x versus 9.33x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BSX
    Boston Scientific
    8.78x 79.12x $4.6B $566M
    PODD
    Insulet
    9.33x 45.19x $597.5M $100.7M
  • Which has Higher Returns BSX or RMD?

    ResMed has a net margin of 12.41% compared to Boston Scientific's net margin of 26.88%. Boston Scientific's return on equity of 8.96% beat ResMed's return on equity of 25.56%.

    Company Gross Margin Earnings Per Share Invested Capital
    BSX
    Boston Scientific
    67.86% $0.38 $32.6B
    RMD
    ResMed
    58.6% $2.34 $5.9B
  • What do Analysts Say About BSX or RMD?

    Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 16.91%. On the other hand ResMed has an analysts' consensus of $269.38 which suggests that it could grow by 19.86%. Given that ResMed has higher upside potential than Boston Scientific, analysts believe ResMed is more attractive than Boston Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    BSX
    Boston Scientific
    23 4 0
    RMD
    ResMed
    7 7 1
  • Is BSX or RMD More Risky?

    Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.

  • Which is a Better Dividend Stock BSX or RMD?

    Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.92% to investors and pays a quarterly dividend of $0.53 per share. Boston Scientific pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BSX or RMD?

    Boston Scientific quarterly revenues are $4.6B, which are larger than ResMed quarterly revenues of $1.3B. Boston Scientific's net income of $566M is higher than ResMed's net income of $344.6M. Notably, Boston Scientific's price-to-earnings ratio is 79.12x while ResMed's PE ratio is 26.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.78x versus 6.73x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BSX
    Boston Scientific
    8.78x 79.12x $4.6B $566M
    RMD
    ResMed
    6.73x 26.53x $1.3B $344.6M
  • Which has Higher Returns BSX or SYK?

    Stryker has a net margin of 12.41% compared to Boston Scientific's net margin of 8.48%. Boston Scientific's return on equity of 8.96% beat Stryker's return on equity of 15.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    BSX
    Boston Scientific
    67.86% $0.38 $32.6B
    SYK
    Stryker
    64.85% $1.41 $34.2B
  • What do Analysts Say About BSX or SYK?

    Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 16.91%. On the other hand Stryker has an analysts' consensus of $424.43 which suggests that it could grow by 13.64%. Given that Boston Scientific has higher upside potential than Stryker, analysts believe Boston Scientific is more attractive than Stryker.

    Company Buy Ratings Hold Ratings Sell Ratings
    BSX
    Boston Scientific
    23 4 0
    SYK
    Stryker
    13 9 0
  • Is BSX or SYK More Risky?

    Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison Stryker has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.393%.

  • Which is a Better Dividend Stock BSX or SYK?

    Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.87% to investors and pays a quarterly dividend of $0.84 per share. Boston Scientific pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BSX or SYK?

    Boston Scientific quarterly revenues are $4.6B, which are smaller than Stryker quarterly revenues of $6.4B. Boston Scientific's net income of $566M is higher than Stryker's net income of $546M. Notably, Boston Scientific's price-to-earnings ratio is 79.12x while Stryker's PE ratio is 48.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.78x versus 6.37x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BSX
    Boston Scientific
    8.78x 79.12x $4.6B $566M
    SYK
    Stryker
    6.37x 48.13x $6.4B $546M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock